Beth Hecht Sells 16,667 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 16,667 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $6.25, for a total transaction of $104,168.75. Following the sale, the insider owned 1,226,507 shares in the company, valued at $7,665,668.75. The trade was a 1.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Beth Hecht also recently made the following trade(s):

• On Monday, February 2nd, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The stock was sold at an average price of $7.45, for a total transaction of $124,169.15.
• On Friday, January 2nd, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The stock was sold at an average price of $7.43, for a total transaction of $123,835.81.

Xeris Biopharma Stock Performance

Shares of NASDAQ:XERS opened at $6.04 on Friday. Xeris Biopharma Holdings, Inc. has a 1 year low of $3.81 and a 1 year high of $10.08. The stock has a market capitalization of $1.04 billion, a price-to-earnings ratio of -603.40 and a beta of 0.61. The company has a debt-to-equity ratio of 16.10, a current ratio of 2.19 and a quick ratio of 1.35. The company’s 50 day simple moving average is $7.13 and its 200 day simple moving average is $7.60.

Xeris Biopharma (NASDAQ:XERS) last issued its earnings results on Monday, March 2nd. The company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. Xeris Biopharma had a negative return on equity of 5.33% and a net margin of 0.19%.The firm had revenue of $85.81 million for the quarter, compared to the consensus estimate of $86.00 million. As a group, research analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current fiscal year.

Wall Street Analyst Weigh In

XERS has been the subject of several research analyst reports. Oppenheimer reissued an “outperform” rating and set a $18.00 target price on shares of Xeris Biopharma in a research note on Friday, November 7th. Wall Street Zen lowered shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a report on Saturday, November 8th. Weiss Ratings raised shares of Xeris Biopharma from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Wednesday. Piper Sandler raised their target price on shares of Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Finally, Barclays initiated coverage on shares of Xeris Biopharma in a research note on Monday, December 8th. They set an “overweight” rating and a $9.00 target price on the stock. Five investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.08.

Xeris Biopharma News Roundup

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating with a $10 price target and published multi?year EPS upside through 2030, signalling continued analyst conviction in the company’s pipeline and revenue trajectory. HC Wainwright coverage / MarketBeat
• Positive Sentiment: A bullish third?party piece argues Xeris is undervalued given its drug portfolio, which can attract value/growth investors and support longer?term demand for the stock. Seeking Alpha: Undervalued thesis
• Positive Sentiment: Aggregate analyst coverage is summarized as a “Moderate Buy,” which helps underpin investor sentiment versus outright bearish coverage. Consensus rating / American Banking News
• Neutral Sentiment: HC Wainwright published specific near?term estimates (Q1?2026 EPS est. of ($0.03); FY2026 est. $0.06) that give a roadmap for upcoming results but include mixed signals as Xeris transitions toward expected profitability. HC Wainwright estimates / MarketBeat
• Neutral Sentiment: Consensus full?year EPS remains negative (around ?$0.41), so near?term profitability risk persists until revenue and margin trends consistently improve. Consensus estimates / MarketBeat
• Negative Sentiment: Insider Beth Hecht sold 16,667 shares at an average $6.25 on Mar 2 (Form 4 filed), which some investors view as a negative signal about insider conviction or a source of incremental supply. Insider sale alert / InsiderTrades
• Negative Sentiment: HC Wainwright trimmed several mid/long?range EPS forecasts (FY2026?FY2029 revisions downward), reducing some near?term upside and tempering expectations until revenue growth reaccelerates. Forecast revisions / MarketBeat

Hedge Funds Weigh In On Xeris Biopharma

Several large investors have recently modified their holdings of the business. UBS Group AG grew its stake in shares of Xeris Biopharma by 682.4% in the third quarter. UBS Group AG now owns 1,782,734 shares of the company’s stock worth $14,511,000 after purchasing an additional 1,554,869 shares during the last quarter. Vanguard Group Inc. raised its position in Xeris Biopharma by 13.8% during the 4th quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock worth $87,815,000 after purchasing an additional 1,358,760 shares during the last quarter. Qube Research & Technologies Ltd lifted its holdings in Xeris Biopharma by 67.5% during the 2nd quarter. Qube Research & Technologies Ltd now owns 3,089,771 shares of the company’s stock worth $14,429,000 after buying an additional 1,245,188 shares during the period. Goldman Sachs Group Inc. grew its position in shares of Xeris Biopharma by 75.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after buying an additional 1,199,435 shares during the last quarter. Finally, CenterBook Partners LP increased its stake in shares of Xeris Biopharma by 237.7% in the second quarter. CenterBook Partners LP now owns 1,594,229 shares of the company’s stock valued at $7,445,000 after buying an additional 1,122,154 shares during the period. Institutional investors own 42.75% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.